AVEXO
AVEXO™ is KweHealth’s next-generation, cell-free investigational secretome therapy, engineered from GMP-grade amniocytes through a proprietary process that enriches exosomes and extracellular matrix (ECM) proteins. Designed to harness the innate regenerative potential of perinatal tissues, AVEXO™ combines the signaling power of exosomes with the structural support of ECM proteins to restore balance, repair damage, and modulate immune homeostasis.
With its unique polyvalent profile, AVEXO™ is being developed to address some of the most challenging conditions in medicine, including wound healing, chronic pain, musculoskeletal injuries, and orthopedic disorders. By targeting both the cellular environment and immune regulation, AVEXO™ aspires to accelerate tissue repair, reduce inflammation, and improve functional recovery—offering a transformative therapeutic approach where current treatments fall short.
AVEXO™ — advancing the frontier of regenerative healing.
-
AVEXO is a secretome product manufactured from GMP-grade Amniocytes using a proprietary process to enrich perinatal exosomes and ECM proteins.
-
Rich in growth factors, cytokines, microRNAs, mRNAs, antimicrobial proteins, and extracellular matrix components, with anti-inflammatory and anti-fibrotic properties.
-
AVEXO is manufactured for research purposes in an FDA-registered laboratory following aseptic techniques and cGMP-compliant protocols to mitigate contamination risks. Quality assurance testing is performed on all batches to meet FDA standards for safety. Each batch is assessed for exosome quantity, quality, size, content and purity using advanced analytical methodologies.
-
The human amniotic fluid used for production of this product is donated under strict conditions. All donors undergo comprehensive screening and testing to confirm the absence of risk factors for infection from relevant communicable diseases. Testing is conducted by an independent laboratory that adheres to CLIA standards and holds certifications from the FDA, CMS, CAP, and AATB.